Researchers are evaluating Lyell's CD19/20 dual-targeting CAR-T against marketed CD19 CAR T-cell therapies in the second-line refractory large B-cell lymphoma setting.

Ultragenyx recently resubmitted a BLA seeking approval for the gene therapy after the FDA rejected it, and the firm will resubmit it again in response to new questions.

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.

The company is also developing an assay to identify best responders to the therapy, which may include patients with certain lung, pancreatic, and kidney tumors.

The firm is testing the activity of AN9025 in patients with various solid tumors harboring KRAS, NRAS, or HRAS mutations.

Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...

Tommy and Linda Pham founded RSF in 2021 to support R&D into a treatment for UBA5 disorder after their son, Raiden, was diagnosed with the extremely rare and progressive neurological condition. The ...

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...

The agency approved the Keytruda-based regimen after reviewing data from the KEYNOTE-B96 trial, in which Agilent's PD-L1 IHC 22C3 PharmDx test was used to stratify patients.

The firm expects its lead CAR T-cell therapy TPST-2003 to begin a Phase IIb registrational trial by the end of this year.

The FDA has cleared the company's investigational new drug application seeking to begin the Phase I/II FUNCTION-DMD trial.